These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 7164099)

  • 1. Comparative 90-day toxicity of two decarboxylase inhibitors, benserazide and carbidopa, in the rat.
    Rauws AG; Vos JG; Garbis-Berkvens JM; Peters PW; de Vries T; van Logten MJ
    Toxicol Appl Pharmacol; 1982 Nov; 66(2):201-20. PubMed ID: 7164099
    [No Abstract]   [Full Text] [Related]  

  • 2. Genetic toxicity of several antihypertensive drugs possessing a hydrazine group.
    Kitamura J; Mori H; Sugie S; Kawai K
    Res Commun Chem Pathol Pharmacol; 1985 Sep; 49(3):415-22. PubMed ID: 4059657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of some decarboxylase inhibitors on striatal tyramines in the mouse.
    Juorio AV
    Neuropharmacology; 1983 Jan; 22(1):71-3. PubMed ID: 6843786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism.
    Pinder RM; Brogden RN; Sawyer PR; Speight TM; Avery GS
    Drugs; 1976; 11(5):329-77. PubMed ID: 782834
    [No Abstract]   [Full Text] [Related]  

  • 5. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
    Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
    Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [CB 154 in the treatment of Parkinson's disease. Results in combination with L-dopa and decarboxylase inhibitor].
    Meco G; Casacchia M; Zamponi A; Agnoli A
    Acta Neurol (Napoli); 1976; 31(4):479-48. PubMed ID: 1037427
    [No Abstract]   [Full Text] [Related]  

  • 7. Systemic and in vitro effects of GAD and GABA-T inhibitors on AADC activity and of AADC inhibitors on GAD.
    Giorgi O; Rubio MC
    Gen Pharmacol; 1981; 12(4):217-23. PubMed ID: 7250670
    [No Abstract]   [Full Text] [Related]  

  • 8. Dose and sex related effects of aromatic aminoacids decarboxylase inhibitors on serum prolactin in humans.
    Polleri A; Masturzo P; Murialdo G; Carolei A
    Acta Endocrinol (Copenh); 1980 Jan; 93(1):7-12. PubMed ID: 7355667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ethanol, levodopa and inhibitors of extracerebral aromatic L-amino acid decarboxylase: a drug-drug interaction study.
    Messiha FS
    Proc West Pharmacol Soc; 1977; 20():327-31. PubMed ID: 896840
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacokinetics of the decarboxylase inhibitor benserazide in man; its tissue distribution in the rat.
    Schwartz DE; Jordan JC; Ziegler WH
    Eur J Clin Pharmacol; 1974; 7(1):39-45. PubMed ID: 4853605
    [No Abstract]   [Full Text] [Related]  

  • 11. Prolactin response to acute administration of different L-dopa plus decarboxylase inhibitors in Parkinson's disease.
    Ruggieri S; Falaschi P; Baldassarre M; D'Urso R; De Giorgio G; Rocco A; Agnoli A
    Neuropsychobiology; 1982; 8(2):102-8. PubMed ID: 7070643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levodopa with benserazide or carbidopa in Parkinson disease.
    Rinne UK; Mölsä P
    Neurology; 1979 Dec; 29(12):1584-9. PubMed ID: 574221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of levodopa with carbidopa or benserazide in parkinsonism.
    Greenacre JK; Coxon A; Petrie A; Reid JL
    Lancet; 1976 Aug; 2(7982):381-4. PubMed ID: 73849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset.
    Tayarani-Binazir KA; Jackson MJ; Fisher R; Zoubiane G; Rose S; Jenner P
    Eur J Pharmacol; 2010 Jun; 635(1-3):109-16. PubMed ID: 20303948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benserazide decreases central AADC activity, extracellular dopamine levels and levodopa decarboxylation in striatum of the rat.
    Jonkers N; Sarre S; Ebinger G; Michotte Y
    J Neural Transm (Vienna); 2001; 108(5):559-70. PubMed ID: 11459076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of a peripheral decarboxylase inhibitor (carbidopa) on monoamine and neuroendocrine function in man.
    Garfinkel PE; Warsh JJ; Stancer HC; Godse DD; Brown GM; Vranic M
    Neurology; 1977 May; 27(5):443-7. PubMed ID: 558549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Parkinson's disease with carbidopa, a peripheral decarboxylase inhibitor, and levodopa.
    Fermaglich J
    Med Ann Dist Columbia; 1974 Dec; 43(12):587-91. PubMed ID: 4532167
    [No Abstract]   [Full Text] [Related]  

  • 18. Combined use of benserazide and carbidopa in Parkinson's disease.
    Lieberman AN; Goldstein M; Gopinathan G; Neophytides A; Hiesiger E; Walker R; Nelson J
    Neurology; 1984 Feb; 34(2):227-9. PubMed ID: 6538015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and cardiovascular effects of alpha methyldopa in combination with decarboxylase inhibitors.
    Kersting F; Reid JL; Dollery CT
    Clin Pharmacol Ther; 1977 May; 21(5):547-55. PubMed ID: 322921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolism of carbidopa (1-(-)-alpha-hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate), an aromatic amino acid decarboxylase inhibitor, in the rat, rhesus monkey, and man.
    Vickers S; Stuart EK; Bianchine JR; Hucker HB; Jaffe ME; Rhodes RE; Vandenheuvel WJ
    Drug Metab Dispos; 1974; 2(1):9-22. PubMed ID: 4150141
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.